01 April 2013 10:37 [Source: ICIS news]
SINGAPORE (ICIS)--The Indian Supreme Court’s decision on Monday to deny Norvatis’s plea for patent protection of its cancer drug Glivec “discourages future innovation in India”, the Swiss drug major said in a statement.
Norvatis had been denied a patent by the Indian authorities on the grounds that the updated version was only slightly different from its previous form, according to the BBC.
The Supreme Court’s decision means generic drugmakers can continue to sell copies of the drug at lower prices, it added.
"We brought this case because we strongly believe patents safeguard innovation and encourage medical progress, particularly for unmet medical needs,” said Ranjit Shahani, vice chairman and managing director at Novartis India.
“This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options," Shahani added.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections